Core Insights - Crinetics Pharmaceuticals is experiencing early commercial momentum with its product PALSONIFY, which has been adopted by over 125 unique prescribers and has received more than 200 enrollment forms from clinical studies [1][6][2] - The company is transitioning from building a pipeline to establishing a commercial business, with PALSONIFY being its first commercial product launched in the U.S. [2][3] - Crinetics plans to initiate a global phase II/III study for atumelnant in ACTH-dependent Cushing's syndrome, which is characterized as a rare and difficult-to-treat condition [5][12] Commercial Performance - In Q4 2025, Crinetics reported total revenue of $6.2 million, with $5.4 million coming from PALSONIFY [4][16] - The company has seen encouraging formulary momentum, with several top payers adding PALSONIFY to their formularies, often with label-aligned prior authorizations and no step edits [1][6] - Approximately half of the patients are currently reimbursed through commercial or government coverage, while the other half are utilizing the company's Quick Start program [7][6] Financial Overview - Crinetics utilized $326.2 million in cash during 2025, which was favorable compared to the guidance range of $340 million to $370 million [19] - The company ended 2025 with over $1 billion in cash and investments, and after a public offering in January 2026, this amount increased to approximately $1.4 billion [20] - For 2026, the company expects GAAP operating expenses to be between $600 million and $650 million, reflecting increased clinical trials and commercialization activities [21] Pipeline Developments - Atumelnant is the first ACTH receptor antagonist tested in humans and has shown rapid and significant reductions in 24-hour urinary free cortisol in preliminary studies [5][10] - The upcoming EQUILIBRIUM ADCS trial will evaluate safety and efficacy across a range of doses, with a focus on establishing a glucocorticoid replacement strategy [12][13] - Crinetics is also advancing other candidates, including paltusotine for carcinoid syndrome and CRN09682 in oncology, with ongoing clinical trials [14][22] Regulatory Updates - Crinetics received a positive opinion from the CHMP in Europe for PALSONIFY, marking a significant milestone in its global regulatory strategy [22]

Financial Data and Key Metrics Changes - In Q4 2025, the company recognized $6.2 million in total net revenue, comprising $5.4 million from the U.S. launch of PALSONIFY and $0.8 million from a licensing agreement with SKK in Japan [25] - Total revenue for the full year 2025 was $7.7 million, with a cost of product revenue of $1.1 million in Q4 [25][26] - The company ended 2025 with over $1 billion in cash equivalents and investments, excluding $380 million from a public offering in January 2026, bringing total cash to approximately $1.4 billion post-offering [28] Business Line Data and Key Metrics Changes - The launch of PALSONIFY has seen over 200 enrollment forms received in Q4, with more than 125 unique prescribers involved [8][9] - The company is focusing on building a commercial enterprise around PALSONIFY, with a fully integrated team in place to support its launch [10][11] Market Data and Key Metrics Changes - The company is experiencing encouraging formulary momentum with payers, securing wins with top plans in the U.S. for PALSONIFY [9] - Approximately 50% of claims have been pre-reimbursed, with 60% moving into the QuickStart program [63] Company Strategy and Development Direction - Crinetics is transitioning from building a pipeline to establishing a commercial business, aiming to become a leading endocrinology company [7] - The company is focused on launching multiple innovative pharmaceuticals from its pipeline, including paltusotine and atumelnant, while also advancing its nonpeptide drug conjugate program [11][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, highlighting the successful launch of PALSONIFY and ongoing clinical trials for other products [31] - The company is committed to transforming the lives of patients with endocrine diseases and creating long-term sustainable value for stakeholders [31] Other Important Information - The company expects GAAP operating expenses for 2026 to be between $600 million and $650 million, reflecting ongoing investments in clinical trials and commercialization activities [29] - The anticipated increase in operating expenses is due to a full year of commercialization activities supporting PALSONIFY [29] Q&A Session Summary Question: Insights from Phase 2/3 design and previous studies - Management indicated that the structure of the Cushing's disease study is well established, with normalization of urine-free cortisol as a primary endpoint [36][68] Question: Trends in PALSONIFY prescriptions - Management noted positive feedback from prescribers and patients, but refrained from providing specific quantitative trends for the quarter [41][44] Question: Enrollment forms and commercial therapy timeline - Management stated that it is premature to extrapolate the 200 enrollment forms as a consistent run rate, with 50% of patients reimbursed and the other 50% on QuickStart [49][50] Question: Payer dynamics for PALSONIFY - Management reported no significant barriers to treatment access, with most coverage based on labels and a commitment to expedite the QuickStart process [63] Question: ADCS study design and endpoints - Management confirmed that the primary endpoint for the phase 3 study is set by the FDA, focusing on the percentage of patients achieving normal urine-free cortisol [68]

Financial Data and Key Metrics Changes - In Q4 2025, Crinetics Pharmaceuticals recognized $6.2 million in total net revenue, comprising $5.4 million from the U.S. commercial launch of PALSONIFY and $0.8 million from a licensing agreement with SKK in Japan [26] - Total revenue for the full year 2025 was $7.7 million, with a cost of product revenue of $1.1 million in Q4 [26][27] - The company ended 2025 with over $1 billion in cash equivalents and investments, excluding $380 million from a public offering in January 2026, bringing total cash equivalents to approximately $1.4 billion post-offering [29][30] Business Line Data and Key Metrics Changes - The launch of PALSONIFY has seen over 200 enrollment forms received in Q4, with more than 125 unique prescribers involved [8][9] - The company is focusing on building a commercial enterprise around PALSONIFY, with a fully integrated team in place to support its launch [10][11] Market Data and Key Metrics Changes - The company is experiencing encouraging formulary momentum with payers, securing wins with top plans in the U.S. for PALSONIFY [9] - Approximately 50% of claims have been pre-reimbursed, with 60% moving into a Quick Start program [64] Company Strategy and Development Direction - Crinetics is transitioning from building a pipeline to building a business, aiming to establish itself as a leading endocrinology company [7] - The company is focused on launching multiple innovative pharmaceuticals from its pipeline, including paltusotine and Atumelnant, while also advancing its nonpeptide drug conjugate program [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for PALSONIFY and the potential for Atumelnant to address significant unmet needs in treating Cushing's disease [11][25] - The company anticipates that existing cash and investments will be sufficient to fund operations into 2030, allowing for continued investment in clinical trials and commercialization activities [30] Other Important Information - The company has received a positive CHMP opinion for PALSONIFY in the treatment of acromegaly, marking a significant milestone for its European regulatory path [32] - The EQUILIBRIUM ADCS study is designed to efficiently assess the safety and efficacy of Atumelnant in treating ACTH-dependent Cushing's syndrome [25] Q&A Session Summary Question: Insights from phase II/III design and previous studies - Management noted that the structure of the Cushing's disease study is well precedented, with normalization of urine-free cortisol as a primary endpoint [34][37] Question: Trends in PALSONIFY prescriptions - Management expressed satisfaction with the launch and noted positive feedback from prescribers and patients, but refrained from providing specific quantitative trends [41][42] Question: Enrollment forms and commercial therapy timeline - Management indicated that it is premature to extrapolate the 200 enrollment forms as a run rate, and about 50% of patients are reimbursed for commercial therapy [49][50] Question: Payer dynamics for PALSONIFY - Management reported positive progress in market access with no significant barriers to treatment, and ongoing engagement with payers [63][64] Question: ADCS study design and endpoints - Management confirmed that the primary endpoint for the phase III study is set by the FDA, focusing on the percentage of patients achieving normal urine-free cortisol [68][69]

Core Insights - Crinetics has achieved significant milestones in 2025, marking it as a breakthrough year for the company [3] - The company successfully obtained approval for a broad label for Palsonify, aimed at treating acromegaly, coinciding with its PDUFA date [3] Company Development - Crinetics has evolved from discussing its first molecule, CRN808, to focusing on Palsonify and building a comprehensive pipeline and business [2] - The management emphasizes the transition from merely developing drugs to establishing a sustainable business model [2]

Crinetics Pharmaceuticals Conference Call Summary Company Overview - **Company**: Crinetics Pharmaceuticals (NasdaqGS:CRNX) - **Date**: January 05, 2026 - **Key Products**: Palsonify (for acromegaly), Atumelnant (for congenital adrenal hyperplasia, CAH) Key Points Industry and Market Context - The call discussed the acromegaly market, highlighting approximately **36,000 people** living with the condition in the U.S. [7] - The company aims to address the challenges faced by patients with acromegaly, many of whom have been stalled by inconsistent treatments [7] Product Launch and Performance - **Palsonify**: - Launched successfully in Q4 2025, with over **200 enrollment forms** processed [12] - Achieved **$5 million** in unaudited net revenue for the fourth quarter [12] - The launch strategy focuses on engaging both actively managed patients and those who have not been diagnosed [9] - Positive patient feedback has been reported, with many switching from injectable therapies to Palsonify [10] - **Atumelnant**: - Positioned to transform CAH treatment, aiming to provide a new standard of care without the side effects of high-dose steroids [5] - Data indicates a robust benefit-risk profile, with ongoing phase three studies planned [6] - The drug is designed to selectively block the ACTH receptor, potentially leading to significant reductions in adrenal androgens [17] Clinical Data and Studies - **Atumelnant Phase 2 Study**: - Cohort four results showed sustained reductions in androstenedione (A4) levels while tapering glucocorticoids [22] - A4 reductions were observed even with glucocorticoid doses reduced to physiological levels [24] - The study demonstrated a **67% reduction** in A4 levels in cohort four [33] - **Safety Profile**: - Atumelnant has been well tolerated with no serious adverse events reported across over **750 weeks** of patient exposure [30] - Common adverse events included headache and fatigue, typical for this patient population [29] Future Plans and Expectations - The company is optimistic about the upcoming **phase 3 CALM CAH study**, targeting **150 patients** to evaluate Atumelnant's safety and efficacy [30] - The study aims to demonstrate a statistically significant difference in achieving normal A4 levels while on physiological glucocorticoid doses [31] - Crinetics plans to continue expanding its pipeline, with additional candidates like paltusotine for carcinoid syndrome and CRN9682 for SST2-expressing cancers [36] Commercial Strategy - The company emphasizes commercial execution as a top priority, with a focus on building relationships with healthcare providers and payers [11] - Early formulary inclusions have been secured, and the company is actively engaging with payers to ensure patient access [12][70] Additional Insights - The company is committed to addressing the long diagnostic delays for acromegaly, which can take **5 to 10 years** [9] - The patient ambassador program aims to leverage patient experiences to enhance awareness and support for Palsonify [13] Conclusion Crinetics Pharmaceuticals is positioned for growth in the endocrine treatment market, with successful product launches and promising clinical data for Atumelnant. The company is focused on improving patient outcomes and expanding its market presence through strategic commercial initiatives and ongoing clinical studies.

Core Insights - Crinetics Pharmaceuticals Inc. is awaiting a pivotal FDA decision on its New Drug Application for paltusotine, a treatment for acromegaly, expected on September 25, 2025 [1] - If approved, paltusotine will be the first oral nonpeptide SST2 agonist, providing a significant alternative to current injectable treatments [2] - The drug's efficacy is supported by strong Phase 3 trial results, showing effective IGF-1 control and symptom relief [3] Company Positioning - The FDA decision represents a critical juncture for Crinetics, with approval potentially validating years of development and introducing a new treatment option for acromegaly [4] - The company is proactively preparing for a potential launch by enhancing its sales and medical teams and engaging with healthcare providers [4] - A negative outcome could adversely affect Crinetics' pipeline and market perception, as the company's valuation is closely tied to paltusotine's success [5] Financial Standing - As of June 30, 2025, Crinetics holds $1.2 billion in cash and equivalents, providing financial stability to pursue multiple programs regardless of the FDA's decision [6] - The company's financial position allows it to maintain operational momentum into 2029, independent of the outcome of the paltusotine application [6]

Core Insights - Crinetics Pharmaceuticals reported a GAAP revenue of $1.0 million for Q2 2025, exceeding the consensus estimate of $0.61 million, but the GAAP net loss per share widened to $(1.23), larger than the anticipated $(1.08) per share, due to increased R&D and administrative expenses [1][5][6] Financial Performance - GAAP revenue for Q2 2025 was $1.0 million, a 150% increase from $0.4 million in Q2 2024 [2] - GAAP net loss per share was $(1.23), a 30.9% increase from $(0.94) in Q2 2024 [2] - Research and Development expenses rose to $80.3 million, up 37.8% from $58.3 million in Q2 2024 [2] - Selling, General & Administrative expenses doubled to $49.8 million from $24.8 million in Q2 2024 [2] - The company reported a net loss of $(115.6) million for the quarter, compared to $(74.1) million in Q2 2024 [1][6] Product Pipeline and Development - The company focuses on developing oral therapies for rare endocrine diseases, with lead products including paltusotine for acromegaly and carcinoid syndrome, and atumelnant for congenital adrenal hyperplasia and Cushing's disease [3][11] - Paltusotine's New Drug Application (NDA) review is on track, with a target FDA decision date of September 25, 2025 [7] - Atumelnant is in Phase 2 trials for CAH, with Phase 3 studies planned for both adult and pediatric populations [8] Strategic Initiatives - The company is preparing for its first commercial drug launch, focusing on regulatory approvals, clinical trial effectiveness, and building relationships with healthcare professionals [4][10] - The CrinetiCare platform is being established to support patient outreach and education ahead of the potential launch of paltusotine [10] Cash Position and Future Outlook - As of June 30, 2025, the company had $1.2 billion in cash, cash equivalents, and investments, expected to fund operations into 2029 [15] - Full-year cash use for 2025 is estimated between $340 to $370 million, reflecting readiness for commercial launch and ongoing late-stage trials [15] - Management did not provide formal guidance for future revenue or earnings, focusing instead on the upcoming FDA decision for paltusotine [14]

Company Overview and Financial Status - Crinetics has a strong financial position with $1.3 billion in cash, cash equivalents, and investments[31] - The company anticipates its first commercial launch this year and holds IP rights into the 2040s[31] Pipeline Programs and Focus - Crinetics is developing paltusotine, with a PDUFA date in September 2025, for acromegaly[27] - The company is developing CRN12755, a TSHR antagonist, for Graves' Hyperthyroidism and Graves' Orbitopathy (TED), with plans for an IND submission[123] - Crinetics is advancing CRN10329, an SST3 agonist, for Autosomal Dominant Polycystic Kidney Disease (ADPKD), with IND-enabling studies ongoing[150] - The company is developing CRN09682, a nonpeptide drug conjugate (NDC), targeting SST2-expressing tumors, currently in Phase 1/2 study[254] Market and Patient Reach - Graves' Hyperthyroidism affects over 3 million individuals in the US, with a significant portion developing TED[75] - ADPKD affects approximately 145,000 diagnosed patients in the US, with 50% developing end-stage kidney disease[130, 131] - The addressable patient population for Graves' Orbitopathy (TED) is up to approximately 170,000 incident cases[120]

Core Points - Crinetics Pharmaceuticals granted non-qualified stock option awards for 102,350 shares and restricted stock unit (RSU) awards for 77,875 shares to 46 new non-executive employees as part of the 2021 Employment Inducement Incentive Award Plan [1][2] - The stock options have an exercise price of $31.99 per share, equal to the closing price on July 10, 2025, and will vest over four years [2] - Crinetics Pharmaceuticals is focused on developing novel therapeutics for endocrine diseases and related tumors, with lead candidate paltusotine in clinical development for acromegaly and carcinoid syndrome [3] Summary by Category Stock Options and RSUs - The stock options and RSUs were granted as inducements for new employees under the 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4) [1][2] - Stock options will vest 25% after one year, with the remainder vesting in 36 equal monthly installments, contingent on continued employment [2] - RSUs will vest in equal annual installments over four years, also dependent on continued employment [2] Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company specializing in endocrine diseases and tumors [3] - The company’s lead candidate, paltusotine, is the first investigational oral selective somatostatin receptor type 2 nonpeptide agonist [3] - Other drug candidates in development include treatments for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with a focus on orally delivered small molecules [3]

Summary of Crinetics Pharmaceuticals (CRNX) 2025 Update / Briefing Company Overview - **Company**: Crinetics Pharmaceuticals (CRNX) - **Focus**: Development of novel therapies for endocrine diseases, particularly targeting underserved patient populations Key Points and Arguments Strategic Focus and Pipeline Development - Crinetics was founded to address the needs of patients with endocrine disorders, emphasizing the importance of understanding patient experiences and needs in drug development [10][12][53] - The company has transitioned from a discovery-focused entity to a development and commercialization company, with a pipeline that includes several promising candidates [22][24] Pipeline Highlights - **Paltusotine**: A first-in-class somatostatin receptor agonist for acromegaly, which has progressed through clinical trials and is currently in the NDA process with a PDUFA date set for September 25 [12][22] - **Atomelanet**: An ACTH receptor antagonist for congenital adrenal hyperplasia (CAH) and Cushing's disease, which entered clinical trials in 2021 [20][22] - **CRN 12,755**: A TSH receptor antagonist in development for Graves' disease, which is expected to address both hyperthyroidism and Graves' orbitopathy [55][70] TSH Receptor Antagonist Program - **Graves' Disease**: Affects approximately 1% of the U.S. population (about 3 million people), with significant symptoms including hyperthyroidism and thyroid eye disease [56][81] - Current treatments have limitations, including risks associated with ablative therapies and adverse effects from antithyroid drugs [60][61] - **CRN 12,755**: Demonstrated efficacy in preclinical models, showing potential to suppress thyroid hormone production and mitigate symptoms of orbitopathy [70][72] Market Opportunity - The addressable patient population for Graves' disease therapies is substantial, with an annual incidence of new diagnoses up to 170,000 and a significant number of patients suffering from moderate to severe orbitopathy [81][82] - The company aims to provide a single oral therapy that effectively treats both hyperthyroidism and orbitopathy without the adverse effects associated with current treatments [77] Future Directions - Upcoming poster presentation at the ENDO conference to share additional data on CRN 12,755 [82] - Progressing through IND enabling activities with plans for a Phase 1 healthy volunteer study to establish safety and pharmacokinetics [82] Other Important Content - Emphasis on the company's culture and commitment to patient engagement, which informs their drug development process [12][53] - The importance of having backup candidates in development to mitigate risks associated with lead compounds [46][50] - The dynamic nature of GPCRs and the complexity of drug discovery, highlighting the challenges and strategies in developing effective therapies [33][36] This summary encapsulates the key points from the Crinetics Pharmaceuticals briefing, focusing on the company's strategic direction, pipeline developments, market opportunities, and future plans.